Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01961830 · ClinicalTrials.gov registry record · Phase 1
Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers
A Phase 1 study, sponsored by Meiji Seika Pharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01961830 is a Phase 1 study that has completed, run by Meiji Seika Pharma Co.. The registered enrollment target is 42 participants.
The verdict
NCT01961830, a Phase 1 study, has completed, sponsored by Meiji Seika Pharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a single-center, open-label, single-dose study. The primary objective is to determine Epithelial Lining Fluid (ELF) levels of ME1100 after a single orally inhaled dose. The secondary objectives are to determine systemic exposure to inhaled ME1100 and to assess tolerability and safety of a single dose of ME1100 inhalation solution.
Interventions
- DRUG ME1100 inhalation solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01961830
The ClinicalTrials.gov registry entry for NCT01961830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meiji Seika Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ME1100 inhalation solution is the first listed.
NCT01961830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01961830 about?
NCT01961830 is a clinical study titled "Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers". This is a single-center, open-label, single-dose study. The primary objective is to determine Epithelial Lining Fluid (ELF) levels of ME1100 after a single orally inhaled dose. The secondary objectives are to determine systemic exposure to inhaled ME1100 and to assess tolerability and safety of a si...
What is the current status of trial NCT01961830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2013-09.
What interventions are being tested in trial NCT01961830?
The interventions under investigation include: ME1100 inhalation solution (DRUG).
Who is sponsoring clinical trial NCT01961830?
This trial is sponsored by Meiji Seika Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.